ALTIS BIOSYSTEMS
Rapidly screen for anti-inflammatory leads using Repligut® Planar
Inflammatory bowel diseases (IBD) are a major health concern worldwide, with an estimated 1.6 million cases in the US alone. While there are many treatments available, they are often ineffective and can cause harmful side effects.
A major reason successful IBD therapies remain elusive is because current model systems cannot replicate key mechanistic aspects of the epithelial inflammatory response in humans.
That's why we developed InflammaScreen™ Services, a suite of pre-qualified, multiple readout assays using our flagship model RepliGut® Planar Transverse Colon. These assays are specifically designed to both speed up discovery and improve the human relevance of gastrointestinal inflammation focused drug discovery.
Ways to benefit from an InflammaScreen Study
Triage larger chemical sets to identify most promising candidates
Compare candidates to gain clarity on overlapping or discerning functionalities
Achieve fast iterative turnaround while optimizing structure and function
Save money and time by eliminating ineffective molecules early
Getting Started
Unlock
Start your project and ship compounds to Altis
Test
Test up to 10 compounds per plate for anti-TNF signaling phenotypes
Get Results
Our experienced project leads get your results to you in as little as 3 weeks
Results from InflammaScreen™ Services will give you clinically relevant insights into how your test drugs will interact with the inflamed intestinal epithelium using a standard format with rapid turnaround times
View and download the Inflammascreen 96-well platemap to start designing your experiment. Our project leads are available to support you throughout
The ability to test for anti-inflammation is more accessible than ever
Schedule your consultation with our experts today